RHAPSODY

Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification
RHAPSODY logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 3
Grant agreement number
115881

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
8 130 000
EFPIA in kind
8 169 249
Other
2 189 500
Total Cost
18 488 749

Summary

Improving diabetes prevention and treatment is the ultimate goal of the RHAPSODY project. Type 2 diabetes affects 285 million people globally and that number is rising fast. RHAPSODY brings together experts from universities, large pharmaceutical companies and biotechs. Their goal is to add to our understanding of the factors that drive the progression of pre-diabetes to diabetes, and the deterioration of the condition of people with diabetes. RHAPSODY aims to develop novel biological markers that will aid in the diagnosis of type 2 diabetes, and the identification of different sub-groups of patients. This information will also help to inform clinical trial design and the development of new strategies to prevent and treat diabetes.

Achievements & News

Taking a tailored approach to type 2 diabetes
December 2018

Diabetes is a chronic and incurable illness linked to blood sugar that has traditionally been divided into type 1 and type 2. Type 2 accounts for the vast majority of cases – some 285 million – and its prevalence is expected to soar over the coming decade. Amid this backdrop, IMI's RHAPSODY project set out to look more closely at type 2 in a bid to develop targeted treatments for the condition, which can vary significantly and cause serious complications such as kidney failure. ###In a major development, RHAPSODY – in conjunction with others including IMI's BEAT-DKD project – has broken type 2 diabetes down into five subgroups which need different treatments and have different progressions. And this, the researchers believe, has the potential to revolutionise how doctors deal with diabetics. ‘What RHAPSODY is really about is individualising diabetes treatment,’ says vice project coordinator Leif Groop of Lund University in Sweden. ‘For too long, we have had the situation that one size fits all.’  The subgroups grew out of a Swedish study known as ANDIS involving more than 13 000 diabetics and initiated by Groop. It monitored not only patients' blood sugar but also factors such as insulin resistance and secretion, as well as age. The study has since been replicated, including in China.

Scientists identify five subtypes of diabetes
March 2018

Scientists have identified five subtypes of diabetes, a finding that will pave the way for more personalised treatments for the disease. The work, published in The Lancet Diabetes and Endocrinology, was funded in part by IMI through the projects BEAT-DKD and RHAPSODY. ###Currently, two main types of diabetes are recognised, and diagnosis is through a measurement of a patient’s blood sugar levels. In this study, scientists monitored over 13 000 newly-diagnosed diabetes patients, analysing blood sugar levels, insulin resistance, insulin secretion, and age of onset among other things. This revealed five distinct groups of patients with different risk levels for certain complications associated with diabetes. For example, patients in group 2 (‘severe insulin-deficient diabetes’) are at greatest risk of eye disease, while patients in group 3 (‘severe insulin-resistant diabetes’) had the highest incidence of kidney damage. ‘Current diagnostics and classification of diabetes are insufficient and unable to predict future complications or choice of treatment,’ said Leif Groop of Lund University in Sweden. ‘This is the first step towards personalised treatment of diabetes.’ Until now, the team has only studied people in Sweden and Finland; they now plan to carry out similar studies in China and India, to see if their findings apply in different ethnic groups.

Participants Show participants on map

EFPIA companies
  • Eli Lilly and Company Limited, Basingstoke, United Kingdom
  • Institut De Recherches Servier, Suresnes, France
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Novo Nordisk A/S, Bagsvaerd, Denmark
  • Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany
Universities, research organisations, public bodies, non-profit groups
  • Academisch Ziekenhuis Groningen, Groningen, Netherlands
  • Academisch Ziekenhuis Leiden, Leiden, Netherlands
  • Azienda Ospedaliera Citta Della Salute E Della Scienza Di Torino, Torino, Italy
  • Centre Hospitalier Regional Et Universitaire De Lille, Lille, France
  • Centre National De La Recherche Scientifique Cnrs, Paris, France
  • Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany
  • Imperial College Of Science Technology And Medicine, London, United Kingdom
  • Institut National De La Sante Et De La Recherche Medicale, Paris, France
  • Itä-Suomen yliopisto, Kuopio, Finland
  • Kobenhavns Universitet, Copenhagen, Denmark
  • Lunds Universitet, Lund, Sweden
  • SIB Institut Suisse De Bioinformatique, CH-660-0733998-3, Genève, Switzerland
  • Stichting Vumc, Amsterdam, Netherlands
  • Technische Universitaet Dresden, Dresden, Germany
  • Universita Di Pisa, Pisa, Italy
  • Universite De Lausanne, Lausanne, Switzerland
  • Universite Paris Diderot - Paris 7, Paris, France
  • University Of Dundee, Dundee, United Kingdom
  • University of Oxford, Oxford, United Kingdom
  • Université Libre de Bruxelles, Bruxelles, Belgium
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Lipotype, Dresden, Germany
  • Sciprom SARL, St-Sulpice, Switzerland
Third parties
  • Universite De Lille

CONTACT

Project coordinator
Bernard THORENS
UNIVERSITE DE LAUSANNE
bernard.thorens[at]unil.ch